"The U.S. Food and Drug Administration today notified Ranbaxy Laboratories, Ltd., that it is prohibited from manufacturing and distributing active pharmaceutical ingredients (APIs) from its facility in Toansa, India, for FDA-regulated drug product"...
Sermorelin acetate for injection increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Sermorelin is similar to the native hormone (GRF [1-44]-NH 2 ) in its ability to stimulate GH secretion in humans. Pharmacokinetics
In subcutaneous administration of 2 mg sermorelin to 12 normal volunteers, peak concentrations of sermorelin were reached in 5-20 minutes. The mean absolute bioavailability after SC administration is about 6%.
After intravenous administration of 0.25-1.0 mg Sermorelin® to 12 normal volunteers, the mean volume of distribution ranged between 23.7-25.8 liters.
No metabolism studies have been performed in humans.
Sermorelin is rapidly cleared from the circulation, with clearance values in adults ranging between 2.4-2.8 L/min. The halflife of Sermorelin is short, 11-12 minutes after either intravenous or subcutaneous administration.
Gender/Age: No gender data are available in pediatric patients. In normal adults, the clearance of sermorelin in men and women is similar. No age data are available.
Renal/Hepatic Insufficiency: No data are available.
Last reviewed on RxList: 7/16/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Sermorelin Acetate Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.